101 related articles for article (PubMed ID: 9353372)
1. P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier.
Kusuhara H; Suzuki H; Terasaki T; Kakee A; Lemaire M; Sugiyama Y
J Pharmacol Exp Ther; 1997 Nov; 283(2):574-80. PubMed ID: 9353372
[TBL] [Abstract][Full Text] [Related]
2. Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats.
Fujii S; Setoguchi C; Kawazu K; Hosoya K
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4650-8. PubMed ID: 24985475
[TBL] [Abstract][Full Text] [Related]
3. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
Zong J; Pollack GM
J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
[TBL] [Abstract][Full Text] [Related]
4. Role of P-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of Glycyrrhiza glabra.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Yu XQ; Chowbay B; Wen JY; Duan W; Chan E; Li XT; Cao J; Li CG; Xue CC; Zhou SF
Pharm Res; 2007 Sep; 24(9):1668-90. PubMed ID: 17551811
[TBL] [Abstract][Full Text] [Related]
5. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
Dagenais C; Zong J; Ducharme J; Pollack GM
Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
[TBL] [Abstract][Full Text] [Related]
6. Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux.
Suzuki T; Miyata M; Zaima C; Furuishi T; Fukami T; Kugawa F; Tomono K
J Pharm Sci; 2010 Jan; 99(1):413-21. PubMed ID: 19530072
[TBL] [Abstract][Full Text] [Related]
7. Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier.
Chen X; Zhou ZW; Xue CC; Li XX; Zhou SF
Xenobiotica; 2007 Jun; 37(6):635-78. PubMed ID: 17614009
[TBL] [Abstract][Full Text] [Related]
8. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
[TBL] [Abstract][Full Text] [Related]
9. Effect of the Mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice.
Desrayaud S; De Lange EC; Lemaire M; Bruelisauer A; De Boer AG; Breimer DD
J Pharmacol Exp Ther; 1998 May; 285(2):438-43. PubMed ID: 9580581
[TBL] [Abstract][Full Text] [Related]
10. The use of microdialysis techniques in mice to study P-gp function at the blood-brain barrier.
Sziráki I; Erdő F; Trampus P; Sike M; Molnár PM; Rajnai Z; Molnár J; Wilhelm I; Fazakas C; Kis E; Krizbai I; Krajcsi P
J Biomol Screen; 2013 Apr; 18(4):430-40. PubMed ID: 23204072
[TBL] [Abstract][Full Text] [Related]
11. Possible involvement of cationic-drug sensitive transport systems in the blood-to-brain influx and brain-to-blood efflux of amantadine across the blood-brain barrier.
Suzuki T; Fukami T; Tomono K
Biopharm Drug Dispos; 2015 Mar; 36(2):126-37. PubMed ID: 25410756
[TBL] [Abstract][Full Text] [Related]
12. Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine.
Emi Y; Tsunashima D; Ogawara K; Higaki K; Kimura T
J Pharm Sci; 1998 Mar; 87(3):295-9. PubMed ID: 9523981
[TBL] [Abstract][Full Text] [Related]
13. Effect of capillary efflux transport inhibition on the determination of probe recovery during in vivo microdialysis in the brain.
Sun H; Bungay PM; Elmquist WF
J Pharmacol Exp Ther; 2001 Jun; 297(3):991-1000. PubMed ID: 11356921
[TBL] [Abstract][Full Text] [Related]
14. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain.
Zhao R; Pollack GM
Biochem Pharmacol; 2009 Oct; 78(8):1052-9. PubMed ID: 19523457
[TBL] [Abstract][Full Text] [Related]
15. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
[TBL] [Abstract][Full Text] [Related]
16. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine.
Desrayaud S; Guntz P; Scherrmann JM; Lemaire M
Life Sci; 1997; 61(2):153-63. PubMed ID: 9217274
[TBL] [Abstract][Full Text] [Related]
17. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
Liu X; Cheong J; Ding X; Deshmukh G
Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats.
Lemaire M; Bruelisauer A; Guntz P; Sato H
Cancer Chemother Pharmacol; 1996; 38(5):481-6. PubMed ID: 8765444
[TBL] [Abstract][Full Text] [Related]
19. In vivo induction of P-glycoprotein expression at the mouse blood-brain barrier: an intracerebral microdialysis study.
Chan GN; Saldivia V; Yang Y; Pang H; de Lannoy I; Bendayan R
J Neurochem; 2013 Nov; 127(3):342-52. PubMed ID: 23777437
[TBL] [Abstract][Full Text] [Related]
20. Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier.
Ishiguro N; Nozawa T; Tsujihata A; Saito A; Kishimoto W; Yokoyama K; Yotsumoto T; Sakai K; Igarashi T; Tamai I
Drug Metab Dispos; 2004 May; 32(5):519-24. PubMed ID: 15100174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
